EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: TRK fusions are oncogenic drivers in a variety of tumors, many involving the CNS. Larotrectinib, a selective FDA- and EMA-approved TRK inhibitor, demonstrated a 79% objective response rate (ORR) and a 35.2-month median duration of response (DoR) in adult and pediatric patients with vario...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Goto, Hiroaki, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Schulte, Johannes, Kang, Hyoung Jin, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Reeves, John A, Brega, Nicoletta, Childs, Barrett H, Laetsch, Theodore W, Ziegler, David S, Doz, François
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Early Phase Clinical Trials
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715507/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.132
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker